With the launch of ITMAT the NIHR Imperial BRC is pleased to announce an inaugural call for experimental medicine proposals to exploit ITMAT’s core platform technologies. It aims to promote and encourage the ‘pull-through’ of discovery science from the Faculties of Medicine, Engineering and Natural Sciences within Imperial College London into potential clinical applications.
The intention of this call is to provide seed funding support to pilot experimental medicine projects that are based on a workable hypothesis and can demonstrate reasonable promise of success. Our aim is to provide a boost to these promising projects, to provide the additional data and evidence that will support Imperial researchers to apply for larger, follow-on grants from other funders within a period of 12-15 months.
The Institute for Translational Medicine and Therapeutics (ITMAT) at NIHR Imperial Biomedical Research Centre (BRC) is virtual institute built upon core facilities across the College and Trust. Its aim is to support the acceleration of fundamental discoveries into improvements in human health and economic benefit.
ITMAT includes platforms in genomic (and metagenomic), metabonomic and imaging technologies and health informatics, as well as the NIHR Wellcome Trust Imperial Clinical Research Facility (ICRF) and one of the largest tissue collections in Europe. ITMAT offers BRC co-funding for proof-of-concept studies across the translational divide, and postgraduate programmes at the interface of basic and clinical sciences. The Institute particularly promotes multidisciplinary research, pulling through biomedical applications from engineering and physical sciences discovery science, and strategic commercial partnerships.
More information about the core platforms of ITMAT is detailed in Annex 1 of the guidance documentation.